Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Carcinoma, Hepatocellular 4Advanced Solid Tumors 3Neoplasms 2Advanced Lung Cancer 2Tislelizumab 1Stomach Neoplasms 1Solid Tumor 1SCLC 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1High-Risk Resectable NSCLC 1Colorectal Neoplasms 1Advanced/Metastatic Solid Malignancies 1Advanced or Metastatic Solid Tumors 1Advanced Solid Tumor 1Advanced Non-Small Cell Lung Cancer 1Adenocarcinoma of Lung 1

Interventions

Radiotherapy 6Carboplatin 6Pemetrexed 5Cisplatin 5pembrolizumab 4Paclitaxel 4Docetaxel 4sargramostim 3Taxes 3Bevacizumab 32-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a 3trametinib 2Radiotherapy, Conformal 2Platinum 2Etoposide 2Erlotinib Hydrochloride 2Cetuximab 2vandetanib 1tetrathiomolybdate 1spartalizumab 1sintilimab 1romidepsin 1ribociclib 1nazartinib 1naporafenib 1motexafin gadolinium 1motesanib diphosphate 1methoxyamine 1fludarabine phosphate 1canakinumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Adenocarcinoma of Lung × sintilimab × Clear all
NCT04861948 2022-10-04

IBI188 Combination Therapy in Solid Tumors

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Terminated
9 enrolled
SarcomaThoracic

Adenocarcinoma of Lung, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡